Crisugabalin Besilate - Haisco Pharmaceutical Group
Alternative Names: HSK-16149Latest Information Update: 28 May 2024
At a glance
- Originator Haisco Pharmaceutical Group
- Class Analgesics; Small molecules; Urologics
- Mechanism of Action Calcium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Neuropathic pain; Postherpetic neuralgia
- Phase II Neuralgia; Postoperative pain
- No development reported Diabetic neuropathies
Most Recent Events
- 28 May 2024 No recent reports of development identified for phase-I development in Diabetic-neuropathies(Combination therapy, In volunteers) in China (PO, Capsule)
- 20 May 2024 Haisco Pharmaceutical Group plans a phase III trial for Neuropathic pain in China (PO) in May 2024 (NCT06422117)
- 19 Apr 2024 Haisco Pharmaceutical initiates a phase II trial for Neuropathic pain in China (PO) (NCT06490484)